Stent thrombosis following 2 drug-eluting stent implantations for coronary bifurcation lesion: a single-center analysis
- PMID: 20718906
- DOI: 10.1111/j.1540-8183.2010.00565.x
Stent thrombosis following 2 drug-eluting stent implantations for coronary bifurcation lesion: a single-center analysis
Abstract
Background: The incidence of stent thrombosis (ST) following 2 drug-eluting stent (DES) implantations for coronary bifurcation lesions needs to be identified.
Methods: From April 2004 to April 2009, 705 consecutive patients with true bifurcation lesions who underwent a double stenting procedure with DES at the Fu Wai Hospital were analyzed.
Results: Six (0.85%) patients had a definite ST, all of them had an early (4 acute and 2 subacute) definite ST. Probable ST occurred in 4 patients; in all of these cases, the event occurred early and was adjudicated because of the occurrence of sudden death within 30 days of the procedure. Therefore, a total of 10/705 (1.42%) patients had a definite or probable ST. Possible stent thrombosis was adjudicated only in 1 patient 371 days after the initial PCI in whom the cause of death was unexplained. Compared to the patients without definite and probable ST, patients with definite and probable ST were older, had more unstable angina, lower LVEF, and more left main bifurcation lesions (63.2 +/- 8.9 vs. 56.8 +/- 10.9 yrs; P = 0.049, 100% vs. 64.7%; P = 0.018, 50.6 +/- 9.9 vs. 60.3 +/- 12.4%; P = 0.019 and 70.0% vs. 36.1%; P = 0.043). Logistic analysis results indicated that only LVEF (OR 0.92, 95% CI 0.87-0.93; P = 0.017) was associated with definite and probable ST.
Conclusions: The present study indicates that modern 2-DES technique for bifurcation lesions was comparatively safe with a low incidence of ST.
Similar articles
-
Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.Circulation. 2009 Feb 10;119(5):680-6. doi: 10.1161/CIRCULATIONAHA.108.803528. Epub 2009 Jan 26. Circulation. 2009. PMID: 19171853 Clinical Trial.
-
Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.Am J Cardiol. 2007 Dec 1;100(11):1619-24. doi: 10.1016/j.amjcard.2007.07.013. Epub 2007 Oct 10. Am J Cardiol. 2007. PMID: 18036358
-
Long-term follow-up of patients with sirolimus-eluting stents for treatment of bare-metal in-stent restenosis.Int J Cardiol. 2010 Apr 15;140(2):219-25. doi: 10.1016/j.ijcard.2008.11.029. Epub 2008 Dec 2. Int J Cardiol. 2010. PMID: 19049847
-
Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550. Coron Artery Dis. 2010. PMID: 19952925 Review.
-
Drug-eluting stent thrombosis.Minerva Cardioangiol. 2008 Feb;56(1):127-37. Minerva Cardioangiol. 2008. PMID: 18432175 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous